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Emerging evidence has shown that the extracellular vesicles (EVs) regulate various biological processes and can control cell
proliferation and survival, as well as being involved in normal cell development and diseases such as cancers. In cancer treatment,
development of acquired drug resistance phenotype is a serious issue. Recently it has been shown that the presence of multidrug
resistance proteins such as Pgp-1 and enrichment of the lipid ceramide in EVs could have a role in mediating drug resistance.
EVs could also mediate multidrug resistance through uptake of drugs in vesicles and thus limit the bioavailability of drugs to treat
cancer cells. In this review, we discussed the emerging evidence of the role EVs play in mediating drug resistance in cancers and
in particular the role of EVs mediating drug resistance in advanced prostate cancer. The role of EV-associated multidrug resistance
proteins, miRNA, mRNA, and lipid as well as the potential interaction(s) among these factors was probed. Lastly, we provide an
overview of the current available treatments for advanced prostate cancer, considering where EVs may mediate the development
of resistance against these drugs.
1. Introduction
Extracellular vesicles (EVs) are vesicles secreted by cells [1,
2], they are involved in mediating communication between
cells by transferring signaling molecules, initiating a variety
of cellular processes [2, 3]. The role of EVs in normal cellular
growth and development has been reported as well as in the
context of disease progression and cancer metastasis [4–6].
Exosomes and ectosomes are subclasses of secreted EVs;
they have both been extensively characterized and shown to
be functionally active in a number of studies [7–9]. The exo-
somes are nanosized vesicles, formed through intracellular
budding at the multivesicular bodies (MVB). The biogenesis
of exosomes is mediated by the action of Endosomal Sorting
Complex Required for Transport (ESCRT) or by the lipid
ceramide ([1, 2, 10], Figure 1). The MVB is an organelle
involved in trafficking of vesicles from late endosomes to
the plasma membrane, to mediate secretion [2, 11]. As such,
exosomes contain MVB-associated proteins as well as RNAs
encapsulated in a lipid bilayer with a specific composition of
lipids, rich in sphingomyelin, cholesterol, and glycophospho-
lipid [3, 12–14]. The ectosomes or microvesicles are vesicles
bud from plasma membrane with a diameter up to 1 𝜇m.
The ectosomes also have a specific lipid composition as
they are enriched in phosphatidylserine. The exposure of
phosphatidylserine on the cell surface is a characteristic of
ectosome secretion [15]. Ectosome biogenesis is triggered
by plasma membrane activation including intracellular cal-
cium influx, mediated by ARF-6 and interactions between
cytoskeletal resident proteins actin andmyosin [1, 9, 16]. Oth-
ers such as oncosomes, prostasomes, exosome-like vesicles,
and viruslike vesicles are also members of EVs [2, 17]. The
oncosomes are newly characterised EVs and are large vesicles
(∼0.8 𝜇m)which bud at the plasmamembrane by “amoeboid”
migratory cancer cells [18].
Understanding EV biogenesis has helped to differentiate
exosomes and ectosomes; however classical ultracentrifuga-
tion and density gradient methodologies could not purely
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Figure 1: Schematic representative of ectosome and exosome secretion. Ectosomes or microvesicles are defined as extracellular vesicles
which form through budding from plasma membrane. The exosomes are formed intracellularly, as proteins destined for exosome secretion
are sorted in endosomes and packaged for exosome secretion through MVB pathways. Cross talk between MVB and endosomes has been
reported as lysosomal markers such as LAMPs are found to be coisolated in secreted exosomes. Cells also secrete other types of vesicles such
as oncosomes, prostasomes, and viral-like particles.
separate the subclasses of EVs, in particular to separate
exosomes from other members of the EVs [2, 19]. Emerging
evidence has shown the diversity of EVs; in particular, the
previously characterized exosomes are not a homogenous
population of vesicles [8]. As such, it was proposed to use
the term EVs to include all secreted vesicles, even though
classification based on biogenesis is still used in various
publications [1, 2, 20].
Studies have explored EVs as potential biomarkers for
various diseases, as the protein and RNA content of EVs has
been shown to resemble the cell of origin [21, 22]. EV-derived
protein glypican-1 has been shown to specifically indicate the
presence of pancreatic cancer, indicating the real potential
of EVs as a cancer biomarker [23]. Recently, it is becoming
more accepted that EV secretion is not always constitutive
as originally thought but is likely to be a cellular response
toward changes in their environment. Exposure of cells to an
effector can alter the EV content and their secretion process.
For example, changes in cellular pH levels and exposure of
cells to hypoxia growth conditions can alter the EV secretion
[24, 25].
EVs have also been looked at as natural delivery agents
for several treatments. By exploiting the “natural” path for
vesicle endocytosis, EVs can bypass the immune system
with no or low cytotoxic effects [26, 27]. This has been
tested in melanoma cancer, as treatment of cancer with
EVs containing the MAGE3 peptide has shown promising
results, with no grade II toxicity [28]. EVs have been
reported to internalize into cells through clathrin mediated
endocytosis and micropinocytosis in PC12 cells [29] and
in KRas expressing MiaPaCa-2 cells [30]. The cytoskeleton
seems to play a role in this process [31]. However, due to
the heterogenous nature of EVs, other mechanisms such as
caveolin-dependent and caveolin-independent endocytosis
and lipid raft mediated endocytosis were also observed [32–
34]. As a shuttle mechanism between cells, EVs have been
demonstrated to transfer prion and tau proteins as well as
prion RNA [35, 36]. The transmission of prion protein (PrP)
shows the role EVs play in the mechanism of transmissible
neurodegenerative disorders [37].
In this review, we will discuss and assess the recent
developments in the reported role of EVs in mediating drug
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resistance in cancer. We then discuss the potential role of
how EVs could be involved in mediating the progression of
prostate cancer to a more advanced, castrate resistant form of
the disease. It is beyond the scope of this review to discuss
in detail the many mechanisms of drug resistance; in-depth
reviews on this topic have been published and are referred to
in this paper.
2. The Emerging Role of EVs in
Mediating Drug Resistance in Cancers
Acquired drug resistance is a major obstacle in cancer ther-
apy. Drugs can be transported into target cells by diffusion,
transport (by the action of transporters), or endocytosis (such
as immunotoxins) [38]. Drug resistance accounts for cases
of treatment failure by altering the absorption, metabolism,
and/or efflux of drugs from the target cells. Drugs can also
induce mutations of the targets and inhibit pathways for cel-
lular apoptosis, leading to resistance.Thedevelopment of new
drugs with increased sensitivity and reducing patients’ side
effects toward treatment, while effective, can unfortunately
induce the development of new pathways involved in drug
resistance.
Cancer cells are capable of developing multidrug resis-
tance (MDR). The acquired resistance toward a particular
drug could lead to resistance toward other drugs with differ-
ent structures and targets. Cancer cells do not respond equally
towards drugs due to their distinctive genetic make-up and
the expression of various oncogenes or tumor suppressor
genes. Alteration of the cell cycle and checkpoints as well
as expression of drug efflux pumps can contribute toward
development of MDR [38, 39]. Changes in genetic or epige-
netic factors and alteration in the interaction between host
and tumor microenvironment also contribute toward drugs
resistance [38, 39]. Tumor microenvironment can create a
physical barrier, slowing the absorption of drugs by target
cells and reducing the impact of oxygen radicals [40], thus
reducing the effect of drugs in the body. In prostate cancer,
chemotherapy drugs can prompt the secretion ofWNT16B by
the surrounding fibroblast cells, which then activates cellular
survival Wnt pathways in prostate cancer cells, PC3 [41].
Furthermore, increasing evidence has shown that while drugs
can cause apoptosis in the majority of a cell population, a
small percentage of cells can survive [42, 43]. These cells,
known as Cancer Stem Cells (CSC), express cell survival
pathways BCL2/NF-𝜅B; they are able to self-renew and have
pluripotent capacity [44–46].The ability of CSC to self-renew
is thought to drive its malignant phenotype and could be
responsible for progression of cancer into a more advanced
form of the disease.
Apart from their specific cell surface markers, CSC also
express drug efflux pumps, the ABC drug transporters (ATP-
binding cassette ormultidrug resistance (MDR) protein) [47–
49]. The characteristic expression level of ABC transporters
in tumors has proposed the use of these proteins as biomark-
ers [50]. The ABC transporter protein superfamily is gener-
ally found at the plasma membrane and is recently shown
to be present in EVs [51, 52]. Forty-eight members of ABC
superfamily are found in humans [53, 54] including P-gp
and multidrug resistance-associated protein (MRP) protein
family.TheABC transporters maintain low intracellular drug
concentrations and allow CSC to survive under therapy. It is
hypothesized thatMDR cell lines entrap drugmolecules from
their cytosol into acidic vesicles [55].
The multidrug resistance-1 (MDR1 or ABCB1) is the
most characterized member of the ABC superfamily, also
sometimes referred to as P-gp (P-glycoprotein). P-gp is able to
transport a range of molecules, including amphipathic drug
compounds, chemotherapy agents (such as doxorubicin),
lipid, steroids, and peptides. P-gp activity is highly sensitive to
its lipid environment [56].The expressions of P-gp in cancers
vary. For example, colon and kidney cancers have been shown
to express high levels of P-gp, while ovary, breast, melanomas,
lymphomas, lung, and multiple myelomas cancers express
low levels of P-gp, even though P-gp expression elevates upon
acquired drug resistance. Various strategies to overcome
MDR by inhibiting the ABC transporters have been tested
in phase III clinical trials with minimal success [57]; this
may indicate that additional pathways are involved in the
development of acquired MDR.
The members of ABC transporter family play a role in
maintaining cellular homeostasis, by maintaining cellular
lipid bilayers and transporting fatty acids and sterols in
the body [58]. Chen et al. have reported that ABC trans-
porters play a role in sequestration of drugs into intracel-
lular organelles, as shown by accumulation of cisplatin in
melanosomes [59], limiting the efficacy of drugs. It has been
shown that MDR can also be mediated by changes in the
membrane lipid ceramide [60]. The presence of P-gp has
allowed the conversion of ceramide to sphingolipids, a major
constituent of phospholipid membrane [61]. P-gp may be
involved in the encapsulation of drugs into vesicles, which
would then be exocytosed by cells [62]. P-gp has recently been
shown to function through its association with F-actin and p-
ERM [63].
Another study in pancreatic cancer has strengthened
the benefit of targeting exosome pathways. In a pancreatic
cancer cell model, GAIP interacting protein C terminus
(GIPC, a regulator of G protein signaling) has been shown to
modulate the exosome secretion and content. Interestingly, in
the GIPC-depleted cells, the secreted exosomes contain high
expressions of ABCG2, a member of the ABC transporter
protein superfamily [64].
The presence of ABC transporters in exosomes has also
been shown in breast and prostate cancers, where chemother-
apy drug, docetaxel, can increase the presence of ABC
transporters in secreted exosomes [51, 52, 65]. Docetaxel,
a microtubule-targeting drug, decreases glucosylceramide
synthase and sphingosine kinase-1 and increases ceramide
synthase genes [66], confirming the potential to combine
therapies by targeting ceramide and ABC transporters in a
clinical setting. Cotargeting EV pathways would then be a
promising avenue to overcomeMDR in cancers, even though
the pathways in which EV-derived ABC transporters can
mediate MDR are relatively unexplored. Other molecules
shown to mediate MDR, such as DeltaNp73 in colon cancer
[67], have also been investigated for their role in mediating
MDR through EVs such as exosomes.
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The EV member ectosomes have also been shown as
regulators for MDR. A study using ectosomes secreted
by the adriamycin-resistant breast cancer cell line, MCF-7,
can transfer Ca2+-permeable channels, TrpC5, to endothe-
lial cells. The TrpC5 then stimulates the expression of P-
gp through activation of the transcription factor NFATc3
(nuclear factor of activated T cells isoform c3), mediating the
development of MDR in endothelial HMEC cells [68].
Apart from the presence of MDR-associated proteins,
EVs can be involved in mediating resistance for drugs
by sequestration of drugs in vesicles. It was reported in
cisplatin-resistant melanoma cells that cisplatin is found in
secreted exosomes [69]. Cisplatin is an alkylating agent that
binds to DNA bases causing cross-links and breaks in DNA
strands, interferingwithDNA replication [70]. Encapsulation
of cisplatin in exosomes is shown to be pH dependent.
Accumulation of cisplatin has been shown in EVs when cells
are grown in acidic extracellular pH rather than in neutral
pH [69]. Exosome secretion and uptake are also enhanced in
low pH [71], highlighting the importance of the extracellular
environment in regulating the exosome secretion process.
3. The Emerging Role of EV Lipids in
Mediating MDR
Recent reports have highlighted the role of EVs in regulating
cellular lipid homeostasis. While exosome biogenesis is gen-
erally described as mediated by ESCRT protein complexes,
Trajkovic et al. have shown that the lipid ceramide is able to
regulate exosome secretion independently from the function
of the ESCRT machinery [10]. Interestingly, ceramide, which
is enriched in exosomes, is also known to mediate MDR [10].
The presence of ceramide in exosomes initially appears to
be a downstream action of ceramide biosynthesis, as inhibi-
tion of neutral sphingomyelinases, enzymes which hydrolyse
sphingomyelin to ceramide, can inhibit exosome secretion
[10]. However, further studies in astrocytes have shown
that ceramide in return can alter the exosome secretion, as
treatment with extracellular ceramide stimulated exosome
secretion in neutral sphingomyelinase 2 (nSMase2) deficient
astrocytes cells.These cells do not naturally secrete exosomes;
however, addition of extracellular C18 ceramide can stimulate
exosome secretion in these cells [72].
Ceramide is a bioactive lipid; it has multiple signaling
roles in endothelial cells, macrophages, and fibroblasts [73].
Ceramide accumulation can be mediated by various stim-
uli such as radiation [74], TNF-alpha [75], chemotherapy
drugs [66], and natural anticancer agents (such as curcumin
and capsaicin [76, 77]). Ceramide is capable of inducing
apoptosis; cotreatment using P-gp antagonist and ceramides
increases the rate of cellular death [61]. This process is medi-
ated by alteration of mitochondrial membrane permeability
through oligomerization of ceramide channels and reduction
of prosurvival Bcl-2 proteins inmitochondria.The disruption
ofmitochondrial membrane permeability leads to generation
of reactive oxygen species (ROS), which lead to apoptosis
through caspase activation and mitogen-activated protein
kinases (MAPKs)-dependent and -independent pathways
[78, 79].
The exogenous ceramide could also induce secretion
of ABC transporters in exosomes. For example, in breast
cancer, C6 ceramide-induced secretion of breast cancer
resistance protein (BCRP/ABCG2-associated exosomes) and
inhibition of nSMase2 restored the cellular BCRP. This study
suggests that lipid biosynthesis plays a role in recruiting ABC
transporters into exosomes. Treatment with nuclear receptor
antagonists, farnesoid X receptor antagonist guggulsterone
and retinoid X receptor agonist bexarotene, increased the
concentration of intracellular ceramide and reduced the
BCRP protein in MDA-MB-231 cells [80], suggesting the role
of ceramide-enriched exosomes in mediating MDR through
ABC transporters.
Interestingly, a recent study has demonstrated that ceram-
ide may not be the only lipid which is important in this pro-
cess. A study using Synthetic Exosome-Like Nanoparticles,
where the ratio of ordered lipids (lipid raft) versus disordered
lipids (phospholipids) was equal to 6.0 (SELN6.0), inhibited
the Notch-1 pathway in pancreatic cancer MiaPaCa-2 cells.
The activation of NF-𝜅B leads to expression and the secretion
of SDF-1alpha, a chemokine, which then activates the Akt
survival pathway [81]. These accumulative findings, however,
suggest that maintaining lipid homeostasis is also crucial in
overcoming MDR in cancer therapy and that EVs could be
important players in this process.
4. EV-Derived RNA: An Upstream Regulator of
Acquired MDR?
While the exosomal lipids and ABC transporters in EV have
emerged as important players in acquired MDR, exosomal
RNA has recently been looked at as a player in this process.
A recent study has shown that exosomal RNA could mediate
MDR through interaction between stroma and cancers.
Boelens et al. have reported the role of noncoding transcripts
and transposable elements in stroma-derived exosomes in
stimulating the activation of receptor RIG-I, which, in turn,
activates the transcription factor STAT1-dependent signaling
and Notch-3 in breast cancer cells, and accentuates the
therapy resistance in tumor-initiating cells [82]. The EV-
derived RNA may mediate MDR by regulating expression
levels of drug efflux transporters or enzymes involved in lipid
homeostasis, which would then disrupt the cellular signaling
between the tumor and its microenvironment.
Reports have shown that exosomes-derived miRNAs are
involved inMDR.ThemiR-222 increases the cellular survival
in a docetaxel resistant breast cancer cell line MCF-7 [83].
A paper has also reported that secreted miR-221/222 in
exosomes could mediate transfer of tamoxifen resistance in
MCF-7 cells through downregulation of P27 and ERalpha
[84]. In an ovarian cancer model, miR-21-3p has been shown
to induce cisplatin resistance in A2780 cells, by targeting
NAV3 gene [85].
While these accumulative findings strengthen the role
of EV-derived miRNA, a report has also shown association
between EV-derived mRNA levels and cancer. The mRNA
levels of O(6)-methylguanine DNA methyltransferase and
APNG (alkylpurine-DNA-N-glycosylase) are found to be
enriched in tumor exosomes obtained from patients’ blood
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Figure 2: Current treatment options for advanced prostate cancer.
Several classes of drugs (red circles) have been tested to target
prostate cancer. These drugs inhibit various pathways known to
regulate cancer proliferation and survival. A more personalized
prostate cancer treatment has been developed through cancer
immunotherapy (green circle), by activating patients’ own cell
mediated immunity against prostate cancer.
and correlate with the level found in tumor cells [86], indi-
cating the potential role on EV-derived mRNA in mediating
MDR.
5. Treatment Options for
Advanced Prostate Cancer
Prostate cancer is the most prevalent cancer in men world-
wide and the second highest cause of cancer-related death
in men after lung cancer [87]. Male hormones, androgens,
are required for normal cell and cancer cell growth and
maintenance. The androgens bind to the androgen receptor
(AR) and are transported into the nucleus to initiate DNA
transcription mechanisms.
Removal of the prostate through surgery followed by
radiation therapy and first-line androgen deprivation therapy
for men with primary prostate cancer is suboptimal. Within
two years, 25–40% of cases develop castrate resistant prostate
cancer and continue to progress with metastatic disease [88].
Several classes of drugs/treatments have been developed to
interfere with oncogenes/oncoproteins known to be involved
in the progression of prostate cancer into a more advanced
form of the disease (Figure 2; see also Table 1).
Targeting the AR has remained the main treatment
for advanced prostate cancer. The AR is a steroid nuclear
receptor; it is transcribed from the AR gene located on
chromosome Xq11-12 [89, 90]. AR gene consists of eight
exons, which encode four functional motifs: an amino-
terminal domain, a DNA-binding domain (DBD), a hinge
region, and a ligand-binding domain (LBD) [91–93]. The
amino-terminal domain contains a transactivation domain,
AF1, which is the primary transcriptional regulatory region.
The LBD contains the secondary transcriptional regulatory
region,AF2.TheDBD is composed of two zinc fingers that are
critical to DNA recognition and binding. The hinge domain
of AR contains the nuclear localization signal which regulates
the transactivation potential. The hinge domain is involved
in intranuclear mobility of the AR and provides a site for
binding of various androgen response elements as well as
coactivators/corepressors [94].
Antiandrogens are commonly used in therapy to treat
advanced prostate cancer. Androgen deprivation therapy
(ADT) aims to limit the availability of androgens to bind
to and activate AR, inhibiting the prostate cancer growth.
ADT involves administering luteinizing-hormone-releasing
hormone agonists or antagonists to disrupt the feedback
loop within the hypothalamic gonadal axis, suppressing
testosterone production by the testes. It has been reported
that some prostate cancer cells are able to survive ADT and
continue to maintain AR signaling [95–97]. AR antagonists,
such as enzalutamide (MDV3100) or bicalutamide (Casodex),
are designed to inhibit AR signaling by replacing the natural
ligand DHT [98]. Bicalutamide (Casodex), enzalutamide
predecessor, has shown some agonistic effect in cells which
express high level of AR. Bicalutamide also increases AR
recruitment to the enhancer region, thus increasing expres-
sion of AR regulated genes, such as PSA. Enzalutamide binds
to AR with eightfold greater affinity than bicalutamide and
only threefold less affinity than the natural ligand, DHT.
MDV3100 also reduces the efficiency of AR translocation to
the nucleus and impairs the binding of AR to the androgen
response element and other factors that bind to AR [99]. In
2012, a new antiandrogen drug, ARN-509, with no observed
agonistic effectwas tested to treat castration-resistant prostate
cancer (CRPC); it is currently being tested in phase II clinical
trials [100, 101].
Docetaxel and its derivative, cabazitaxel, both belong
to the taxane group and work by disrupting microtubule
dynamics leading to mitotic arrest and apoptosis [103].
Cancer cells are usually rapidly dividing, requiring dynamic
microtubule assembly during mitosis. Docetaxel stabilizes
microtubules by binding to 𝛽-actin, thus inhibiting micro-
tubule disassembly and mediating G2M arrest [122], and
counteracts expression of oncogenes BCL-2 [104]. Prostate
cancer is a relatively slow growing disease; thus, docetaxel
acts by inhibiting AR nuclear translocation in androgen-
dependent prostate cancer rather than stalling the cell cycle
progression [105].
While treatment with docetaxel has been beneficial, 30%
of CRPC patients who receive docetaxel therapy relapse
[123]. Cancer cells can develop resistance to taxanes through
mutations of the tubulin gene, expression of alternative
tubulin isotypes, or drug efflux through multidrug resistant
protein pumps [124]. Treatments combining docetaxel and
Bcl-2 family inhibitors were tested in prostate cancer cell
lines to overcome docetaxel resistance. ABT-263 and ABT-
737 (Bcl-2, Bcl-xL, and Bcl-w inhibitors) enhanced the effect
of docetaxel in inhibiting PC3 cell growth [125]. When given
with prednisone, treatment with docetaxel every three weeks
led to superior survival and improved rates of response
in terms of pain, serum PSA level, and quality of life, as
compared with mitoxantrone plus prednisone [126]. Cabazi-
taxel has recently replaced the mitochondria affecting drugs,
such as mitoxantrone (discussed below), for prostate cancer
patients who progress after docetaxel treatment. Cabazitaxel
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Table 1: Classes of drugs used to treat advanced prostate cancer in the clinic.
Classes Drugs Mechanism(s) References
Antiandrogens
(i) Enzalutamide
(ii) Bicalutamide
(iii) EPI-506
(iv) ARN-509
Inhibition on the activity of androgen receptor or its
splice variant(s) in mediating DNA transcription [95–102]
Microtubule altering agents (i) Docetaxel(ii) Cabazitaxel
Disruption of microtubule; inhibiting AR translocation
to nucleus; counteracting expression of oncogenes
BCL-2
[103–105]
DNA intercalating agents (i) Cisplatin(ii) Satraplatin
Platinum analog drug; creating a DNA adduct
to allow DNA translation; overriding mechanism of
DNA repair
[106, 107]
[108, 109]
ER stress inducers (i) Bortezomib(ii) Estramustine
Inhibition of the 20S proteasome; modulating BCL-2
expression; depolymerizing cytoplasmic microtubules
by binding to tubulin and tau protein
[104, 110–113]
Mitochondria affecting drugs Mitoxantrone
Mitochondria affecting drugs; causing mitochondrial
stress by depolarization of the mitochondrial
membrane; inhibiting topoisomerase II-mediated DNA
intercalation
[114–116]
Steroid synthesis inhibitor (i) Abiraterone(ii) Orteronel
Inhibiting de novo biosynthesis of androgens by
targeting CYP17 in the androgen biosynthesis pathway;
suppressing AR signaling in castrate resistant prostate
cancer
[117–121]
binds to different tubulin isotypes, human albumin, and
lipoproteins and less efficiently to P-gp [127, 128].
Treatment combining ER stress inducers, bortezomib
(Velcade), and docetaxel has been shown to benefit patients.
Bortezomib is an inhibitor of the 20S proteasome, involved
in ubiquitin-mediated protein degradation [110, 111]. Borte-
zomibmodulates BCL-2 expression [104] but does not inhibit
androgen mediated PSA mRNA expression. Bortezomib
stimulates p53 translocation to the nucleus and enhances
its DNA binding causing accumulation of p53-dependent
transcripts in LNCaP pro5 cell line and leading to cell death
[129].
Another ER stress inducer, estramustine (Emcyt), is a
derivative of estrogen (estradiol) [130]. It has been shown
to depolymerise cytoplasmic microtubules by binding to
tubulin [112] and tau protein [113].Themicrotubule and endo-
plasmic reticulum (ER) are interdependent, as prolonged
disruption of microtubules will cause the ER to retract to
the nucleus. This ER extension occurs at the same time
as microtubule formation, by attaching to the growing end
of microtubules and it is dependent on microtubule motor
activity [131, 132].
Estramustine, used in combination with docetaxel,
increases prostate cancer patients’ median survival by two
months in comparisonwith docetaxel alone [133]. In compar-
isonwith a combination ofmitoxantrone and prednisone, the
docetaxel and estramustine combination improves median
survival by nearly two months for men with metastatic,
androgen-independent prostate cancer [134]. To improve the
synergistic effects, a combination of docetaxel, estramustine,
and low-dose hydrocortisone has been trialed; unfortunately,
50% of men with CRPC acquired resistance toward treat-
ments [135].
Satraplatin (JM-216) is an orally bioavailable plat-
inum analog drug that has shown promise for treating
advanced prostate cancer bymediating G2M cell cycle arrest.
Satraplatin is an analog of cisplatin and is effective in prostate
cancer cells that are resistant to cisplatin [106, 107]. Satraplatin
binds to DNA and creates a DNA adduct that is resistant to
DNA nucleotide excision repair protein; it also evades DNA
mismatch repair protein [108, 109].
Mitochondria affecting drugs, such as mitoxantrone
(Novantrone), have also been tested in prostate cancer.
Mitoxantrone blocks the cell cycling phase at S and G2 phase
and is able to inhibit colony formation by prostate cancer
cells in vitro [114]. Cells accumulate the drug within or near
their mitochondria [115], increasing mitochondrial stress by
depolarization of the mitochondrial membrane and causing
release of cytochrome c into the cytosol, increased hydrogen
peroxide production, activation of caspase cascades, and
apoptosis [114]. Treatment with mitoxantrone also causes an
increase in the expression of BCL-XI (a member of the BCL-
2 family) and delays the onset of the p53 pathway. Both of
these pathways are known to be involved in the survival
of prostate cancer cells. BCL-2 is involved in mitochondrial
membrane integrity and is involved in the Akt apoptosis
pathway [136, 137]. Mitoxantrone also inhibits topoisomerase
II-mediated DNA intercalation and generates free radicals
that kill cancer cells [116].
Treatment by inhibiting de novo biosynthesis of andro-
gens in CRPC has recently been investigated by targeting
CYP17. CYP17 catalyzes two key steroid reactions involv-
ing 17alpha-hydroxylase and C(17,20)-lyase in the andro-
gen biosynthesis pathway [117, 118]. The cytochrome P450
enzymes CYP11A1 and CYP17A1 are involved in intratu-
moral conversion of the weak adrenal androgens DHEA
and androstenedione into the AR ligands testosterone and
dihydrotestosterone [138]. CYP17A1 inhibitors, such as abi-
raterone acetate (Zytiga), are sought as a potential effective
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therapy for castrate resistance prostate cancer [117, 119]. How-
ever, a study in castration-resistant VCaP tumor xenografts
shows development of abiraterone resistance. Abiraterone
resistant prostate cancer cells express a T877A mutation
in the AR, such as that found in LNCaP cells, which
is activated by other steroids through CYP11A1-dependent
pregnenolone/progesterone synthesis [138]. In a controlled
COU-AA-302 study, abiraterone plus prednisone signifi-
cantly prolonged median overall survival in chemotherapy-
naive men with metastatic CRPC. Another CYP17 inhibitor,
orteronel (TAK-700) with higher specificity for 17,20-lyase
than for 17𝛼-hydroxylase, has been developed to reduce
abiraterone-induced toxicity. Orteronel is shown to reduce
the expression of PSA (Prostate Specific Antigen), an AR
regulated gene and current clinical biomarker for prostate
cancer, in metastatic CRPC [120].
Both enzalutamide and abiraterone have been designed to
further suppress AR signaling in CRPC. Resistance to enza-
lutamide and abiraterone is indicated by a return of activated
AR signaling. This phenomenon may be mediated by AR
splice variants (AR-Vs), in particular, variant 7 (AR-V7) [121].
TheAR-V7 lacks the LBD, which is the target of enzalutamide
and abiraterone. Interestingly, AR-V7 can remain constitu-
tively active as a transcription factor [121]. Activation of
mutant AR by eplerenone can be inhibited by antiandrogens
(MDV3100, bicalutamide) or abiraterone. Treatment with
abiraterone could overcome resistance caused by activation
of AR by residual ligands or coadministered drugs [139].
Recently, a new drug, EPI-506, which targets the N-terminal
of AR was announced to be tested in prostate cancer patients
[102].
Personalized treatment by implementing cancer immun-
otherapy is being developed for prostate cancer. Sipuleucel-
T (APC8015 or Provenge) is a novel cancer immunotherapy,
which utilizes a recombinant fusion protein (PA2024) con-
sisting of granulocyte macrophage colony-stimulating factor
and prostatic acid phosphatase to stimulate the patient’s T
cells response [140]. Sipuleucel-T has shown a positive effect
in extending survival by median 4.1 months in men with
metastatic CRPC (IMPACT phase III trial data) [141], while
combination with docetaxel does not seem to enhance the
efficacy of this treatment [142].
Recently, a new phase 1/2 clinical trial has been approved
to evaluate thecombination of immunotherapyADXS-PSA and
pembrolizumab.The ADXS-PSA (ADXS31-142) is an investi-
gational Listeria monocytogenes- (Lm-) LLO immunotherapy
to reduce the immunosuppressive activity ofmyeloid-derived
suppressor cells and regulatory T cells in the tumor microen-
vironment. Pembrolizumab (Keytruda) is a humanizedmon-
oclonal antibody that blocks the interaction between pro-
grammed death receptor-1 and its ligands. Combinations of
both agents will be tested in metastatic CRPC patients [143].
6. Can EVs Mediate Drug Resistance in
Prostate Cancer?
Drug resistance is a major problem in the treatment of many
cancers, including prostate cancer. Various roles of EVs in
prostate cancer have been reported; EVs can alter the changes
of tumor fibroblasts to myofibroblasts, as well as promoting
angiogenesis in the tumor microenvironment [144, 145].
Amoeboid prostate cancer can also secrete oncosomes upon
treatment with growth factors, which are involved in cancer
cell migration, invasion, and metastasis [17]. EVs have also
been looked at as a potential source of biomarkers in prostate
cancer [146, 147], while their role in mediating MDR in
prostate cancer has just started to be investigated.
Normal prostate cells express BCRP (ABCG2) and MRP
(ABCC1) [148, 149] but not P-gp (ABCB1) [149], whereas
prostate cancer cells do express P-gp [150]. Corcoran et al.
have shown that exosomes can mediate transfer of docetaxel
resistance through P-gp transport via EVs in aDU145 cell line
[51], even though a mechanism of how exosomal-derived P-
gp could mediate drug resistance was not described.
In a non-EVs study, the contribution of P-gp inmediating
drug resistance in prostate cancer was previously reported. In
a study, prostate cancer cell lines were cotreated with doxoru-
bicin (a gamma topoisomerase poison, which causes DNA
damage) and drugs that are known to partially target the
MDR in tumors (verapamil, cyclosporine A, and tamoxifen)
[151]. Verapamil acts by inhibiting voltage-gatedK+ channels,
which then inhibit the proliferation of LNCaP cells [152].The
cotreatment resulted in a synergistic effect in PC-3 and DU-
145 cells, but not LNCaP cells, indicating the role of P-gp
in PC-3 and DU145 resistance. However, the author has also
reported that low MDR-reversal rates could suggest that an
alternative MDR-independent pathway may be responsible
for triggering drug resistance in prostate cancer [151].
Lipid homeostasis seems to play a major role in drug
resistance in other cancers as discussed above. Disruption of
lipid homeostasis such as treatment with ceramide can also
be utilized to target prostate cancer. Ceramide can enhance
activation of the intrinsic apoptotic pathways and enhance
cell death induced by TNF-alpha in LNCaP cells [153].
Treatment with bioactive ceramide also induces apoptosis
in AR expressing LNCaP prostate cancer cells by causing
nuclear fragmentation and activation of c-Jun N-terminal
kinase (JNK), independent of PKC pathways [79]. In AR
negative prostate cancer cells PC3, ceramide activates the
protein phosphatase 2A (PP2A) and increased p27(kip1)
protein levels via Akt-dependent and Akt-independent path-
ways [154], suggesting some overlaps in pathways influenced
by lipid homeostasis. A natural agent, capsaicin, mediates
cell death through sphingomyelin hydrolysis by nSMase, to
generate ceramide via the ERK and JNK pathways, resulting
in cellular apoptosis in prostate cancer [155]. Alteration of
membrane properties could lower the level of resistance [156],
an area where EVs could contribute.
In a study on docetaxel resistance in prostate cancer, miR-
34a shows clinical relevance. miR-34A could alter cellular
response to docetaxel in prostate cancer cells through BCL-
2, which then target SNCA and SCL7A5 [157]. Treatment
of DU145 cells with fludarabine increase the secretion of
exosome-associated miRNA. While the exosome-associated
miRNA was not identified, fludarabine treatment is shown
to retain the miR-485-3p in parental cells, which could play
a role in resistance through regulation of the transcriptional
repressor nuclear factor-Y which regulates transcription of
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topoisomerase IIalpha, multidrug resistance gene 1, and
cyclin B2 prosurvival genes [158].
7. Conclusion
Prostate cancer is an extremely heterogeneous disease; the
underlying mechanisms for progression to CRPC are com-
plex [138, 159]. Exposure to drugs will prompt tumor cells
to secrete proteins to the external environment, where these
proteinsmediate interaction with stroma, macrophages, den-
dritic cells, and others. Understanding factors that contribute
toward MDR will help patients and clinicians to decide on
the most suitable treatment regime for an individual patient,
increasing the efficacy of drugs, while reducing unnecessary
side effects.
The release of EVs is exacerbated in tumors leading to
their increased presence in bodily fluids of cancer patients
[160–162]. Tumor-derived EVs express an array of antigens
that reflect the originating tumor cells, small RNAs, and
specific composition of lipid bilayers. EVs secreted by a tumor
can trigger an immune response and cellular differentiation
in the tumor microenvironment and they have also been
shown to support tumor escape and growth [144, 145, 163].
The presence of P-gp and ceramide in EVs indicates the
potential role of EV in mediating MDR, even though the
mechanisms by which P-gp and ceramide-derived EVs can
mediate MDR in prostate cancer are not clear. The role
of EVs in mediating MDR could be limited to drugs that
alter the P-gp expression or functions or the lipid ceramide.
Understanding the effect on EV pathways of various drugs
used to target prostate cancer will help us to understand the
role of EVs in mediating MDR in prostate cancer.
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